Cargando…

Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis

INTRODUCTION: To examine the effects of tumour necrosis factor (TNF) blocking therapy on the levels of early mitochondrial genome alterations and oxidative stress. METHODS: Eighteen inflammatory arthritis patients underwent synovial tissue oxygen (tpO(2)) measurements and clinical assessment of dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Biniecka, Monika, Kennedy, Aisling, Ng, Chin T, Chang, Ting C, Balogh, Emese, Fox, Edward, Veale, Douglas J, Fearon, Ursula, O'Sullivan, Jacintha N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239359/
https://www.ncbi.nlm.nih.gov/pubmed/21787418
http://dx.doi.org/10.1186/ar3424
_version_ 1782219175326908416
author Biniecka, Monika
Kennedy, Aisling
Ng, Chin T
Chang, Ting C
Balogh, Emese
Fox, Edward
Veale, Douglas J
Fearon, Ursula
O'Sullivan, Jacintha N
author_facet Biniecka, Monika
Kennedy, Aisling
Ng, Chin T
Chang, Ting C
Balogh, Emese
Fox, Edward
Veale, Douglas J
Fearon, Ursula
O'Sullivan, Jacintha N
author_sort Biniecka, Monika
collection PubMed
description INTRODUCTION: To examine the effects of tumour necrosis factor (TNF) blocking therapy on the levels of early mitochondrial genome alterations and oxidative stress. METHODS: Eighteen inflammatory arthritis patients underwent synovial tissue oxygen (tpO(2)) measurements and clinical assessment of disease activity (DAS28-CRP) at baseline (T0) and three months (T3) after starting biologic therapy. Synovial tissue lipid peroxidation (4-HNE), T and B cell specific markers and synovial vascular endothelial growth factor (VEGF) were quantified by immunohistochemistry. Synovial levels of random mitochondrial DNA (mtDNA) mutations were assessed using Random Mutation Capture (RMC) assay. RESULTS: 4-HNE levels pre/post anti TNF-α therapy were inversely correlated with in vivo tpO(2 )(P < 0.008; r = -0.60). Biologic therapy responders showed a significantly reduced 4-HNE expression (P < 0.05). High 4-HNE expression correlated with high DAS28-CRP (P = 0.02; r = 0.53), tender joint count for 28 joints (TJC-28) (P = 0.03; r = 0.49), swollen joint count for 28 joints (SJC-28) (P = 0.03; r = 0.50) and visual analogue scale (VAS) (P = 0.04; r = 0.48). Strong positive association was found between the number of 4-HNE positive cells and CD4+ cells (P = 0.04; r = 0.60), CD8+ cells (P = 0.001; r = 0.70), CD20+ cells (P = 0.04; r = 0.68), CD68+ cells (P = 0.04; r = 0.47) and synovial VEGF expression (P = 0.01; r = 063). In patients whose in vivo tpO(2 )levels improved post treatment, significant reduction in mtDNA mutations and DAS28-CRP was observed (P < 0.05). In contrast in those patients whose tpO(2 )levels remained the same or reduced at T3, no significant changes for mtDNA mutations and DAS28-CRP were found. CONCLUSIONS: High levels of synovial oxidative stress and mitochondrial mutation burden are strongly associated with low in vivo oxygen tension and synovial inflammation. Furthermore these significant mitochondrial genome alterations are rescued following successful anti TNF-α treatment.
format Online
Article
Text
id pubmed-3239359
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32393592011-12-16 Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis Biniecka, Monika Kennedy, Aisling Ng, Chin T Chang, Ting C Balogh, Emese Fox, Edward Veale, Douglas J Fearon, Ursula O'Sullivan, Jacintha N Arthritis Res Ther Research Article INTRODUCTION: To examine the effects of tumour necrosis factor (TNF) blocking therapy on the levels of early mitochondrial genome alterations and oxidative stress. METHODS: Eighteen inflammatory arthritis patients underwent synovial tissue oxygen (tpO(2)) measurements and clinical assessment of disease activity (DAS28-CRP) at baseline (T0) and three months (T3) after starting biologic therapy. Synovial tissue lipid peroxidation (4-HNE), T and B cell specific markers and synovial vascular endothelial growth factor (VEGF) were quantified by immunohistochemistry. Synovial levels of random mitochondrial DNA (mtDNA) mutations were assessed using Random Mutation Capture (RMC) assay. RESULTS: 4-HNE levels pre/post anti TNF-α therapy were inversely correlated with in vivo tpO(2 )(P < 0.008; r = -0.60). Biologic therapy responders showed a significantly reduced 4-HNE expression (P < 0.05). High 4-HNE expression correlated with high DAS28-CRP (P = 0.02; r = 0.53), tender joint count for 28 joints (TJC-28) (P = 0.03; r = 0.49), swollen joint count for 28 joints (SJC-28) (P = 0.03; r = 0.50) and visual analogue scale (VAS) (P = 0.04; r = 0.48). Strong positive association was found between the number of 4-HNE positive cells and CD4+ cells (P = 0.04; r = 0.60), CD8+ cells (P = 0.001; r = 0.70), CD20+ cells (P = 0.04; r = 0.68), CD68+ cells (P = 0.04; r = 0.47) and synovial VEGF expression (P = 0.01; r = 063). In patients whose in vivo tpO(2 )levels improved post treatment, significant reduction in mtDNA mutations and DAS28-CRP was observed (P < 0.05). In contrast in those patients whose tpO(2 )levels remained the same or reduced at T3, no significant changes for mtDNA mutations and DAS28-CRP were found. CONCLUSIONS: High levels of synovial oxidative stress and mitochondrial mutation burden are strongly associated with low in vivo oxygen tension and synovial inflammation. Furthermore these significant mitochondrial genome alterations are rescued following successful anti TNF-α treatment. BioMed Central 2011 2011-07-25 /pmc/articles/PMC3239359/ /pubmed/21787418 http://dx.doi.org/10.1186/ar3424 Text en Copyright ©2011 Biniecka et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Biniecka, Monika
Kennedy, Aisling
Ng, Chin T
Chang, Ting C
Balogh, Emese
Fox, Edward
Veale, Douglas J
Fearon, Ursula
O'Sullivan, Jacintha N
Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
title Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
title_full Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
title_fullStr Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
title_full_unstemmed Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
title_short Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
title_sort successful tumour necrosis factor (tnf) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239359/
https://www.ncbi.nlm.nih.gov/pubmed/21787418
http://dx.doi.org/10.1186/ar3424
work_keys_str_mv AT binieckamonika successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT kennedyaisling successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT ngchint successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT changtingc successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT baloghemese successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT foxedward successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT vealedouglasj successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT fearonursula successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis
AT osullivanjacinthan successfultumournecrosisfactortnfblockingtherapysuppressesoxidativestressandhypoxiainducedmitochondrialmutagenesisininflammatoryarthritis